CLS Targets MRI-US Fusion-Guided Focal Laser Ablation of Prostate Tumors
Company Goal to Enable Minimally-Invasive, Focal Therapy Procedure to be Performed in anOffice Setting or Clinic under Local AnestheticLund, Sweden – 25 October, 2021 - Clinical Laserthermia Systems AB (publ) (CLS), developer of high precision, image-guided focal laser ablation (FLA) systems, today announced that a new generation of its TRANBERG® Thermal Therapy System is being evaluated for MRI-US, fusion-guided laser ablation for the minimally-invasive, targeted focal therapy of prostate tumors.